SEC Form 4 · accession 0001611517-16-000001
Immune Therapeutics, Inc. · IMUN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Noreen Griffin
Officer — CHIEF EXECUTIVE OFFICER · Director
Period of report
Mar 1, 2016
Accepted (ET)
Mar 30, 2016 · 8:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001559356
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCKF1,F2 | Mar 1, 2016 | J | 500,000 | $0.00 | A | 4,817,710 | D | |
| COMMON STOCKF3,F4 | Mar 10, 2016 | J | 1,000,000 | $0.00 | D | 3,817,710 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares were issues as consideration for a portion past due salary and expenses.
- F2These shares include 2,685,000 held by the Griffin Family Trust, an irrevocable trust for the benefit of the reporting person's children and grandchildren; 704,009 held by Griffin Enterprises Group, LLC which is 50% owned by the reporting person and 50% owned and managed by Robert Wilson, the reporting person's son; and 1,428,701 owned by Noreen Griffin individually.
- F3These shares were originally issued in consideration for past compensation. The shares should have been cancelled in 2015 but were not cancelled due to technical difficulty obtaining proper documentation from the trustee of the Griffin Family Irrevocable Trust.
- F4These shares include 2,685,000 held by the Griffin Family Trust, an irrevocable trust for the benefit of the reporting person's children and grandchildren; 704,009 held by Griffin Enterprises Group, LLC which is 50% owned by the reporting person and 50% owned and managed by Robert Wilson, the reporting person's son; and 428,701 owned by Noreen Griffin individually.